At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Observer-blind, Randomized, Multi-center Trial to Evaluate the Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System (Referred to as Q-Pan H5N8), Given as a Two-dose Series to Adults 18 to 64 Years of Age and 65 Years of Age and Older
In Brief
A Phase 2 clinical trial evaluating FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, and 2 other interventions for Influenza, Human. Completed, enrolled 518 participants across 20 sites.
Detailed Summary
The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (\>=)18 years of age.
Study Details
Timeline
Interventions
Participants received 2 doses of 375\_B vaccine formulation by intramuscular injection in the non-dominant arm.
Participants received 2 doses of 375\_A vaccine formulation by intramuscular injection in the non-dominant arm.
Participants received 2 doses of 750\_B vaccine formulation by intramuscular injection in the non-dominant arm.
Participants received 2 doses of 750\_A vaccine formulation by intramuscular injection in the non-dominant arm.